HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibiting interleukin-19 activity ameliorates esophageal squamous cell carcinoma progression.

AbstractBACKGROUND:
IL-19 is expressed in esophageal squamous cell carcinoma (SCC), but its biological effect on esophageal cancer remains unclear. We determined the correlation between IL-19 expression levels and clinicopathological variables and explored the effects of IL-19 on the esophageal SCC in vivo and in vitro.
METHODOLOGY/PRINCIPAL FINDINGS:
We determined the expression levels of esophageal SCC tissues from 60 patients using immunohistochemistry. We examined the effects of IL-19 on intracellular signaling, cytokines production as well as proliferation, colonization, and migration in the human esophageal SCC cell line CE81T. Monoclonal antibodies (mAbs) against IL-19 (1BB1) and its receptor IL-20R1 (51D) were used to antagonize the effects of IL-19. We injected SCID mice with CE81T cells and then treated them with anti-IL-19 mAb or control IgG every 3 days and determined tumor growth for 32 days. Of the 60 esophageal SCC patients, 36 patients (60%) were IL-19 strongly stained, which was associated with advanced tumor stage. CE81T cells expressed IL-19 and its receptors. IL-19 induced phosphorylation of STAT3, P38, JNK, ERK1/2, Akt, and NF-κB in CE81T cells. IL-19 promoted the proliferation, colonization, and migration of CE81T cells, which were antagonized by 1BB1 and 51D. IL-19 also induced expression of the transcripts of TGF-β, cyclin B1, CXCR4, and MMP-1 in CE81T cells. In CE81T tumor-bearing mice, 1BB1 reduced tumor growth and downregulated TGF-β, cyclin B1, MMP-1, and CXCR4 expression in tumors.
CONCLUSIONS/SIGNIFICANCE:
IL-19 affects the pathogenesis of esophageal cancer. IL-19 mAb (1BB1) is potentially a potent drug for esophageal cancer therapy.
AuthorsChung-Hsi Hsing, Franky Antonius Kwok, Hung-Chi Cheng, Chien-Feng Li, Ming-Shi Chang
JournalPloS one (PLoS One) Vol. 8 Issue 10 Pg. e75254 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID24130695 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • IL19 protein, human
  • Interleukins
  • Receptors, Interleukin
  • interleukin-20 receptor
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, metabolism)
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Esophageal Neoplasms (drug therapy, metabolism)
  • Esophageal Squamous Cell Carcinoma
  • Humans
  • In Vitro Techniques
  • Interleukins (antagonists & inhibitors, metabolism, pharmacology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Real-Time Polymerase Chain Reaction
  • Receptors, Interleukin (metabolism)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: